Current strategy focuses on increasing the level of wt-p53 in cancer cells by either restoring wild-type properties to mutant p53 or preventing the binding of MDM2/MDM4 to wt-p53, thereby blocking its degradation (Duffy et al., 2014). Here, TP53 is linked to cancer.